- Home
- MLYS vs PHAR Comparison
MLYS vs PHAR Comparison
Compare MLYS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- PHAR
- Stock Information
- Founded
- MLYS 2019
- PHAR 1988
- Country
- MLYS United States
- PHAR Netherlands
- Employees
- MLYS N/A
- PHAR N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- PHAR Health Care
- Exchange
- MLYS Nasdaq
- PHAR Nasdaq
- Market Cap
- MLYS 526.1M
- PHAR 618.3M
- IPO Year
- MLYS 2023
- PHAR N/A
- Fundamental
- Price
- MLYS $10.86
- PHAR $8.42
- Analyst Decision
- MLYS Strong Buy
- PHAR Strong Buy
- Analyst Count
- MLYS 2
- PHAR 3
- Target Price
- MLYS $30.00
- PHAR $27.00
- AVG Volume (30 Days)
- MLYS 263.5K
- PHAR 5.6K
- Earning Date
- MLYS 03-20-2025
- PHAR 03-13-2025
- Dividend Yield
- MLYS N/A
- PHAR N/A
- EPS Growth
- MLYS N/A
- PHAR N/A
- EPS
- MLYS N/A
- PHAR N/A
- Revenue
- MLYS N/A
- PHAR $285,745,000.00
- Revenue This Year
- MLYS N/A
- PHAR $20.08
- Revenue Next Year
- MLYS N/A
- PHAR $9.22
- P/E Ratio
- MLYS N/A
- PHAR N/A
- Revenue Growth
- MLYS N/A
- PHAR 30.64
- 52 Week Low
- MLYS $8.58
- PHAR $6.65
- 52 Week High
- MLYS $16.91
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- MLYS 51.57
- PHAR 40.05
- Support Level
- MLYS $9.81
- PHAR $7.95
- Resistance Level
- MLYS $10.79
- PHAR $9.35
- Average True Range (ATR)
- MLYS 0.62
- PHAR 0.52
- MACD
- MLYS 0.15
- PHAR -0.16
- Stochastic Oscillator
- MLYS 100.00
- PHAR 22.76
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.